A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis

Abstract

Papillary thyroid cancer (PTC) accounts for 80–90% of all thyroid malignancies. The tall cell variant (TCV) is a rare aggressive histotype of PTC. We performed a meta-analysis to compare the clinicopathological characteristics and prognostic factors of TCV with those of classical papillary thyroid carcinoma (cPTC). A literature search was performed using the PubMed and EMBASE databases using Medical Subject Headings and keywords. Twenty studies that included 1871 patients with TCV and 75323 patients with cPTC were included in our meta-analysis. Odds ratios and confidence intervals were calculated for each study. Patients with TCV were associated with multifocality, higher TNM stage, extrathyroidal extension, vascular invasion, lymph node metastasis, distant metastasis, BRAF mutation, disease-specific survival, and overall survival. We found that TCV cases were associated with more aggressive clinicopathological characteristics and poorer prognoses than cPTC cases were. Our results suggest that TCV is a high-risk PTC that warrants aggressive treatment and follow-up strategies.

Mulberry anthocyanins improves thyroid cancer progression mainly by inducing apoptosis and autophagy cell death

“…There are four main types of thyroid carcinoma: papillary thyroid carcinoma, medullary carcinoma, undifferentiated carcinoma and follicular thyroid carcinoma [10]. At present, the major therapeutic modality for thyroid papillary carcinoma is surgery combined with radioactive iodine cleaning or a chemical treatment program [11]. However, such treatment methods do not achieve satisfactory response in undifferentiated thyroid carcinoma and medullary thyroid carcinoma due to radiotherapy resistance.…”

Propensity score matching analysis of the prognosis for the rare oxyphilic subtype of thyroid cancer (Hurthle cell carcinoma)

“…The incidence of thyroid cancer has risen rapidly during recent decades [ 1 – 3 ]. Papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) (i.e., differentiated thyroid cancer) account for >90% of all thyroid malignancies and are the most common types of thyroid carcinoma [ 1 , 4 , 5 ].…”

Disease Activity May Not Affect the Prognosis of Coexisting Thyroid Cancer in Acromegalic Patients

“…In our series, those with a controlled acromegaly activity follow ing pituitary surgery and those exposed to high IGF-1 levels about 3-240 months until normalization of IGF-1, were both in remission for DTC (▶table 2), which may suggest that prognosis of DTC was independent of acromegaly activity, gender, age and disease dura tion in our cohort. The only acromegalic patient (#7) who needed multiple RAI doses for remission of thyroid cancer had aggressive histologic findings including the histologic subtype of tall cell, which is reported to be one of the aggressive histologic subtypes of DTC [23]. Therefore, the histopathologic features of that acromegalic pa tient (#7) would also lead to poorer prognosis in non-acromegalic patients as the patient #13 in our control group.…”